Most material SEC filings — October 14, 2026

FF EAI Robotics Ecosystem Inc. (public market cap ~$5.6M) agreed to acquire the robotics business of Faraday Future Intelligent Electric Inc. (FFAI) and Smart Technology Holdings Ltd. (Cayman Seller) for $200M in consideration, payable via 1,315,313 shares of Purchaser Common Stock and 65,475 shares of Purchaser Preferred Stock. The deal involves an equity exchange followed by merger of the robotics entity into a subsidiary. Closing conditioned on regulatory approvals, key employee retention, and Purchaser stockholder approval. Non-compete and employee transition provisions apply post-close.

Evolution Metals (market cap ~$7.1M) reaffirmed FY2027 revenue guidance of $400–460M and FY2026 guidance of $10–11M. The company unveiled a portfolio of eight sintered NdFeB magnet grades (N42SH, N48SH, N46SH, N35SH, N45H, N42H, N48M, N50M) estimated to represent ~75% of global sintered NdFeB magnet revenue and ~52% of volume; seven of eight grades are customer-certified with N42SH in commercial production in Pohang, South Korea. First 13 of 57 ULVAC equipment containers arrived in Pohang; 13 additional machines are being delivered to lift annual capacity to >10,000 metric tons. SmCo magnet production equipment is targeted for mid-2027, timed to DFARS 252.225-7052 expansion effective January 1, 2027. The company will respond to a U.S. Army sources-sought notice for rare earth magnets issued September 28, 2026 (responses due October 28, 2026).

SkyAI announced a self-tender offer on October 15, 2026, to repurchase up to 95% of outstanding common stock, cash pre-funded warrants, crypto pre-funded warrants, and strategic advisor warrants at $3.00 per share/warrant—a 65% premium to the October 9 close and >100% premium to 60-day VWAP. As of October 14, 2026, the company holds ~$204.6M cash and ~210,000 locked SOL (~$21.7M at $103/SOL), representing net asset value backing of 0.95x the offer price. The offer expires October 29, 2026, and the company expects to hold zero SOL post-completion after liquidating holdings at an average $107.51/SOL.

On July 27, 2026, AiRWA Inc. (market cap $42.5M) agreed to acquire Hongkong Best Life Trade Co., Limited via Nova Innovation Tech Ltd for a base purchase price of $50M ($30M paid at close July 30, $13M paid subsequently, $7M remaining). Contingent earn-outs total up to $80M ($30M if Best Life achieves $10M+ 2026 revenue; $50M if $25M+ 2027 revenue). Total acquisition-date fair value: $71.77M ($48.96M cash + $22.81M contingent consideration). Best Life operates cross-border consumer goods e-commerce/distribution in Asia with expansion to UK/US/Canada/New Zealand. Pro forma combined assets: $297.4M; combined net loss FY 2026: $23.6M.

Better Home & Finance Holding Co filed an 8-K/A (amended current report) on 2026-10-14 disclosing a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard under Item 3.01. The filing does not provide specific details on which listing standard was violated, remediation steps, or timeline, only that the company reported this matter to the SEC on or around 2026-10-05. No counterparties, dollar amounts, or specific remediation terms are disclosed in this filing.

On October 7, 2026, Plum Acquisition Corp. IV received notice from its exchange of failure to satisfy continued listing rules or standards, triggering potential delisting proceedings. The filing does not disclose specific listing criteria violated, financial thresholds breached, remediation timeline, or counterparties involved. This represents a critical corporate governance event for a $177.3M public company.

FortuneX Acquisition Corp (SPAC) amended its Business Combination Agreement with WT Realty Group Inc., effective October 13, 2026. The Aggregate Merger Consideration is now fixed at 52,500,000 shares of PubCo Common Stock valued at $525,000,000 ($10.00 per share reference price). Crucially, the consideration is now non-adjustable for cash, debt, working capital, or purchase price adjustments—removing contingency risk from the original agreement dated September 18, 2026.

National Fuel Gas Company announced Board approval for a tax-free separation of its Integrated Upstream and Gathering (IUG) business, targeting H2 2027 completion. Post-separation, National Fuel becomes 100% rate-regulated (~$5B rate base, 1.1M utility customers, 77 Bcf storage, 5 Bcf/d transportation); IUG becomes pure-play Appalachian upstream with 1.2M acres, 5 Tcf proved reserves, 1.1 Bcf/d production, and $0.53/Mcfe cash costs. National Fuel will distribute ≥80.1% of IUG shares to shareholders pro rata (tax-free), retain up to 19.9% for later sale. Both companies retain current leadership; separation preserves integration benefits.

Fermi Inc. executed a binding 15-year lease with TensorWave for 222 MW total power capacity (156 MW critical IT), generating $6.5B contracted revenue over the initial term with 2.5% annual escalators. AMD (A/stable rated) provides credit support beginning after construction completion in early 2028. Project NOI margin estimated at 75%-80%; delivery phases from Q4 2027 through early 2028.

Actuate Therapeutics filed an amended S-1 registration statement on October 14, 2026, registering up to 74,750,000 common shares, an underwriter warrant for 2,616,250 shares, and 2,616,250 underlying shares. Legal counsel (Greenberg Traurig) opined that all securities are duly authorized and validly issuable when paid for per registration terms. This represents the company's public equity offering for IPO purposes.

USBC, Inc. amended its Master Loan Agreement with Payward Interactive, Inc., increasing the maximum available loan commitment from $25M to $40M, effective October 12, 2026. As of the amendment date, USBC had $21M in outstanding principal advances against the $40M commitment, leaving $19M available. The commitment expires October 12, 2027, and USBC pays a 1.0% annual commitment fee on unused balance.

10% owner NIPPON LIFE INSURANCE CO (CRBG) bought 480K shares (~$16.4M) on the open market (0.4% of holdings). Open-market insider purchase — historically a bullish signal.

On October 13, 2026, Silo Pharma purchased all intellectual property and source/object code for 'Reputation Endpoints' web-based software from individual Larry King for 150,000 shares of common stock (par value $0.0001/share). The software, its algorithms, documentation, and all derivatives transfer free and clear; King receives a 12-month lockup on shares, with indemnity capped at fair market value of consideration. Assignor warrants original creation, no third-party infringement, and no harmful code.

On October 9, 2026, AMASS Brands received notice of failure to satisfy continued listing standards, triggering Item 3.01 disclosure requirements. The filing provides no details on which exchange issued the notice, specific listing rule violations, remediation timeline, or potential consequences. The company (total assets ~$28.2M) faces potential delisting without disclosed mitigation plans.

10% owner GOLDENTREE ASSET MANAGEMENT LP (QVCG) bought 1.4M shares (~$16.7M) on the open market (9.6% of holdings). Open-market insider purchase — historically a bullish signal.

Quoin Pharmaceuticals announced October 14, 2026 that the European Medicines Agency granted Orphan Drug Designation for QRX003 for Peeling Skin Syndrome treatment, providing 10 years of market exclusivity in Europe upon approval. This is the eighth regulatory milestone for QRX003 across two indications (Peeling Skin Syndrome and Netherton Syndrome). The company stated it remains on track to initiate the first-ever formal clinical trial in Peeling Skin Syndrome before year-end 2026.

United Therapeutics (UTC) and Liquidia Technologies settled all pending patent litigation (5 cases across multiple jurisdictions). Liquidia pays UTC $185M immediately for past infringement damages (June 2, 2025 onward) plus $145.4M in two installments (Jan 31, 2027 and Apr 30, 2027) for prospective damages from ongoing Yutrepia sales to PH-ILD patients. UTC pays Liquidia $10M to resolve one case. Liquidia must immediately remove PH-ILD indication from Yutrepia label, cease marketing for PH-ILD, and restrict future sales to PAH-only patients. All litigation dismissed with prejudice except claims against individual Robert Roscigno.

Beneficient Financing, L.L.C. (borrower) and Beneficient (Ben Nevada) amended a letter agreement with HH-BDH LLC (lender) dated March 10, 2026, extending the deadline for a $1,000,000 cash payment from an unspecified earlier date to March 31, 2027. No other terms were modified. The lender is Mack Hicks via HH-BDH LLC.

On October 11, 2026, Yext granted CEO Michael Walrath a nonstatutory stock option for 11,000,000 shares at an exercise price of $7.00/share (total intrinsic value $77M if all tranches vest). The award is divided into 14 tranches with performance-based vesting tied to stock price targets ranging from $21.00 to $88.08 over a 10-year performance period, plus a separate retention/repurchase requirement. The grant requires stockholder approval within 12 months; if not obtained, the entire option forfeits. All vesting requires continuous CEO employment.

Equity Bancshares reported Q3 2026 net income of $26.8M ($1.29 diluted EPS) and core EPS of $1.40, with organic loan growth of 11.9% in legacy markets. Critically, the company announced a merger with Lincoln Bancorp (est. to close Q4 2026), which will add ~$1.5B in assets and expand into Iowa. Loan production reached record $379.3M (+20.3% QoQ); total loans $5.4B; deposits $6.2B. Nonperforming assets rose to 0.99% of total assets. Dividend increased 22% to $0.22/share; 711,369 shares repurchased YTD at $44.84 avg. price.

Corvex, Inc. (market cap ~$5.3M) entered an at-the-market (ATM) sales agreement with Chardan Capital Markets LLC dated October 14, 2026, permitting the sale of up to $250,000,000 in common stock over time. The agreement is registered on Form S-3 (File No. 333-298769, filed September 4, 2026, effective September 16, 2026). Chardan will act as sales agent, with compensation per Schedule 2. The company will issue placement notices to direct sales; no specific amount or timeline for actual issuances was disclosed in this filing.

On June 14, 2026, Comtech agreed to sell most of its Satellite and Space Communications (S&S) segment to Wavestream Corporation (Gilat affiliate) for $157.5M in cash. Comtech received a $10M advance payment (retained if deal fails) and expects $128.3M net proceeds at closing (calendar 2026). Contemporaneously, Comtech secured improved terms on senior debt, subordinated debt, and preferred stock, extending covenant holidays to July 31, 2027, deferring prepayment penalties by 1%, and extending preferred redemption rights from Oct 2028 to Oct 2029. Post-closing, Comtech plans $13-15M in transition costs and expects $16-18M annual cost savings within ~1 year, positioning itself as a focused public safety and communications technology company through Allerium.

Infinity Natural Resources reported Q3 2026 derivative contract losses of $64.4M ($1.2M realized + $63.2M unrealized mark-to-market). The unrealized losses stem from revaluation of open hedging positions (oil, natural gas, NGLs) using forward commodity curves; the company holds hedges across 2026-2030 per board-approved strategy. This represents ~23% of current market capitalization as a quarterly non-cash charge.

Vistance Networks' Board approved a special cash distribution of $1.50 per share, payable November 6, 2026, to shareholders of record as of October 26, 2026. This brings total special distributions in 2026 to $16.50 per share. The company will fund this with available cash, including proceeds from the July 1, 2026 sale of Ruckus Networks business.

Verastem, Inc. issued 30,937,500 shares at $8.00/share and 312,503 pre-funded warrants at $7.9999/warrant to Jefferies LLC and Guggenheim Securities LLC (representatives), with Cantor Fitzgerald and B. Riley as co-underwriters. The offering closed October 15, 2026, raising approximately $247.5M in gross proceeds (before underwriting discounts). The pre-funded warrants carry a nominal $0.0001 exercise price, making them near-equivalent to common stock sales.

Zone Frontier Inc. sold its aqueous ozone cleaning products business and subsidiary CleanCore Global Limited to Sanzonate Holdings LLC (controlled by former CEO Clayton Adams) for a $3.35M secured promissory note at 6% interest payable over 18 months ($300K + $850K + $2.2M), plus up to $2.25M in earnout payments tied to Sanzonate's future equity financings at $10M, $17.5M, and $25M pre-money valuations. Zone also received 5% equity in Sanzonate at closing and transferred ~$844K cash to Sanzonate. The note is secured by first-priority lien on transferred intellectual property.

On October 14, 2026, Tron Inc. entered into a Sales Agreement with Clear Street LLC to conduct an at-the-market (ATM) offering of up to $200,000,000 in common stock. Clear Street acts as sales agent under the agreement, which permits the Company to issue and sell shares from time to time via a Form S-3 registration statement (File No. 333-288986). The agreement grants Clear Street commercially reasonable discretion to sell shares subject to specified pricing and volume limits set by the Company in individual placement notices.

Whitney Wolfe Herd (founder) and Beehive Holdings III, LP are exchanging 10.9M shares of Bumble Class A Common Stock (valued at $65.9M based on merger consideration) for common stock of Oak Topco, Inc., the acquisition vehicle. Under the rollover agreement dated October 12, 2026, the investors will receive Topco shares representing 4.60% of Topco's post-closing equity (versus ~95.4% for parent Ithaca Topco). Wolfe Herd terminates employment effective at closing, receiving severance equivalent to 12 months base salary, target bonus, and vested RSU payments. She is subject to 3-year non-compete, non-solicitation, and non-disparagement covenants post-closing.

ClearOne Inc. received a $200,000 unsecured, non-interest-bearing loan from First Finance Ltd. effective October 7, 2026. The loan has no fixed term or maturity date; repayment timing is to be determined by mutual written agreement. The loan is immediately due upon certain events of default (bankruptcy, liquidation, receivership) or upon 5 business days' notice if payment is missed.

Rezolute announced full enrollment of its Phase 3 upLIFT registrational study of ersodetug in tumor hyperinsulinism on October 14, 2026, with 16 participants. The primary endpoint requires ≥56% response rate (95% CI lower bound ≥30%) for statistical significance; preliminary data from first 8 participants showed 7 of 8 met responder criteria (87.5%), with each achieving complete IV glucose discontinuation and no drug-related safety issues. Topline results expected mid-December 2026.

Daniel Paterson retiring as CEO after 15 years; Michael P. Bailey (30+ years biopharma, 25+ oncology) appointed President and CEO effective January 1, 2027, remaining on Board as advisor. Simultaneously, VS-7375 KRAS G12D inhibitor demonstrates robust Phase 1/2 data: 50% confirmed ORR in 2L mPDAC (n=8), 41% in 2L+ (n=22), 43% confirmed ORR in 2L+ NSCLC (n=23), 33% ORR in 3L+ CRC (n=6); favorable safety with 2% discontinuation rate at 900 mg QD; FDA alignment reached on Phase 3 1L mPDAC trial design, planned opening by end-2026.

Eton Pharmaceuticals entered into an exclusive U.S. licensing and supply agreement with Aquestive Therapeutics for LIBERVANT (diazepam buccal film), an Orphan Drug-designated seizure rescue treatment. The product has tentative FDA approval for ages 2–5 and 12+, with a Type 9 NDA pending for ages 6–11 (PDUFA target March 29, 2027). Eton anticipates commercial launch in April 2027, targeting a $450M+ annual U.S. seizure rescue market. Patent protection extends to 2038. Specific upfront, milestone, and royalty payment terms are not disclosed in the filing.

SKYX Platforms Corp. issued a $8,500,000 Senior Secured Promissory Note to Massachusetts Mutual Life Insurance Company and MassMutual Ascend Life Insurance Company on October 13, 2026, as part of a $12.5M total payment to retire Deako Inc.'s existing senior notes upon merger. Payment structure: $2.0M cash at Merger Agreement signing, $2.0M cash at closing, and this $8.5M note split as $2.25M due 120 days post-closing and $6.25M due at 12-month maturity, bearing 12% fixed interest (17% upon default). Note is secured by first-priority lien on substantially all SKYX assets, with change-of-control and delisting as Events of Default.

SkinHealth Systems' board approved a 1-for-20 reverse stock split of Class A common stock, effective October 14, 2026, reducing outstanding shares from ~130.3M to ~6.5M. The split is designed to restore compliance with Nasdaq's $1.00 minimum bid price requirement. The conversion rate of the company's 7.95% Convertible Senior Secured Notes due 2028 will be adjusted proportionately; no fractional shares will be issued, with fractional share holders receiving cash instead.

Oncolytics completed enrollment in its GOBLET Phase 1/2 study evaluating pelareorep combined with checkpoint inhibitors across gastrointestinal cancers. The company will receive final PanCAN grant payment this quarter following Cohort 5 completion. Final Cohort 4 results (pelareorep + atezolizumab in anal cancer) expected Q4 2026; initial Cohort 5 results (pelareorep-based therapy in pancreatic cancer) expected H1 2027. All enrolled cohorts met pre-specified efficacy success criteria; Cohort 4 median overall survival exceeded expectations.

Director Troim Tor Olav (BORR) bought 1.5M shares (~$7.4M) on the open market (3.7% of holdings). Open-market insider purchase — historically a bullish signal.

Educational Development Corporation reported Q2 FY2027 (ended Aug 31, 2026) net revenues of $4.1M (vs. $4.6M prior year), with net loss of $1.6M (vs. $1.3M). Year-to-date revenues fell 25% to $8.8M from $11.7M; YTD net loss increased to $3.0M from $2.4M. Active PaperPie Brand Partners declined to 5,100 from 5,800 Q2-over-Q2, though up 19% from 4,300 at fiscal year-start. CEO highlights cost reduction plan targeting $1.2M in G&A savings and $100K asset write-down in Q1; cash position held near $1.2M. Potential deferred tax asset of $0.28/share awaits return to profitability.

Distribution Solutions Group announced a definitive agreement to acquire GradeEight Holdings, LLC, which operates Winzer (270 franchisees, ~12,000 customers, 65,000+ SKUs across all 50 states, Puerto Rico, Mexico, Canada) and FastServ Supply (8 brick-and-mortar retail locations in Texas and Arkansas). GradeEight generates approximately $110 million in annual sales; the transaction is expected to be accretive to DSG's Adjusted EBITDA margins, funded via existing cash and amended credit facility, closing Q4 2026.

Four Corners Property Trust executed a master agreement with Darden Restaurants extending all 66 Olive Garden and LongHorn leases originally expiring October 2027 by approximately five years, with no rent concessions or capital contributions. Rent continues 1.5% annual increases per existing terms. Six additional leases expiring October 2028 include early extension options.

On October 14, 2026, the FDA expanded the approved indication for ANKTIVA (nogapendekin alfa inbakicept-pmln) plus BCG to include patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with papillary-only tumors. This is the first such approval for papillary-only disease and extends eligibility to approximately 85% of the NMIBC patient population (previously limited to CIS with or without papillary disease). No specific financial terms, partner commitments, or dollar amounts are disclosed in this announcement.

10% owner MCCARTHY KENT C (NUAI) bought 250K shares (~$1.2M) on the open market (2.6% of holdings). Open-market insider purchase — historically a bullish signal.

Director KAMFAR RAMIN (BPRE) bought 428K shares (~$5.5M) on the open market (16% of holdings). Open-market insider purchase — historically a bullish signal.

MaxCyte raised full-year 2026 revenue guidance from $30–32M to $34M (consisting of ~$28M core business revenue vs. prior $25–27M guidance, plus ~$6M SPL Program revenue vs. prior ~$5M). Q3 2026 preliminary revenue: ~$8.1M core business (26% YoY growth) plus >$1.0M SPL Program revenue including $1.0M milestone. Growth driven by accelerated instrument purchases from a large customer moved forward from Q4; company achieved second SPL milestone in 2026 and now supports two pivotal trials with potential approval as early as 2027.

XTI Aerospace announced on October 14, 2026, that Dr. Allan Evans, age 43 and current CEO of Unusual Machines, Inc. (NYSE American: UMAC), has been appointed as a director and Chairman of XTI's Board, returning the board to five members. Jonathan Ornstein was simultaneously designated Vice Chairman. Evans brings drone industry expertise from prior roles at Red Cat Holdings (COO, 2021–2023) and Fat Shark (CEO, 2017–2020, acquired by Red Cat).

Sono-Tek reported first-half FY2027 revenue of $10.89M (up 6% YoY), with gross margin expanding to 55% and operating income up 41% to $1.28M. Medical market sales surged 289% to $7.05M, driven by balloon and stent-coating systems. Post-quarter, the company received $7.19M in orders expected to ship in FY2028. Cash position strengthened to $17.7M with no debt; backlog stands at $9.51M. FY2027 guidance remains flat to modest growth due to timing of large orders, but visibility for FY2028 significantly improved.

Cipher Digital priced $850M (plus optional $150M) of 0.00% convertible senior notes due November 1, 2032, with conversion price of $15.31/share (35% premium to $11.34 stock price on Oct 13, 2026). Concurrently, Cipher exchanged ~$165.9M principal of 2030 notes for ~40.7M shares. Net proceeds ~$835.1M ($982.5M if option exercised) will fund $89.7M capped call costs, Barber Lake project equity, HPC pipeline build-out, and general corporate purposes. Capped call transactions cover conversion shares with $28.35/share cap (150% premium).

Datacentrex began energizing 500+ ElphaPex DG2 Scrypt ASIC miners acquired previously (prepaid). Upon full energization, online Scrypt hashrate increases ~21% from 43.2 TH/s to 52.2 TH/s (~9.0 TH/s gain); total fleet reaches 3,500+ miners; power capacity rises from 12.5 MW to 14 MW. No incremental capex required (miners prepaid).

Netcapital Inc. (market cap ~$2.9M) received notice on October 7, 2026 that it regained compliance with Nasdaq's minimum bid price rule after its stock closed at $1.00+ per share for 10 consecutive business days (September 23–October 6, 2026), resolving a deficiency first flagged February 4, 2026. Simultaneously, the company engaged Adeptus Partners LLC as its new independent auditor (replacing Fruci Associates II, resigned August 12, 2026) to audit and restate consolidated financials for fiscal years 2022–2026 and review interim FY2026 data. The company remains out of compliance with Nasdaq Rule 5250(c)(1) due to failure to file delinquent Form 10-K (FY ended April 30, 2026) and Form 10-Q (Q ended July 31, 2026); it must submit a compliance plan by October 23, 2026.

Flyte Aviation signed a multi-year exclusive partnership with the Philadelphia 76ers effective October 14, 2026, becoming the Official Private Aviation Partner. The deal involves digital/social media collaboration, premium hospitality, fan engagement, corporate partnerships, and in-arena activations (including a 'Halftime Flyte Challenge' promotion). No financial terms, deal value, or explicit duration were disclosed in the filing.